<DOC>
	<DOC>NCT01386268</DOC>
	<brief_summary>To obtain data on safety, efficacy, and tolerability of KOGENATE FS under real-life conditions in its registered indications. The observation period for each patient is up to 6 months.</brief_summary>
	<brief_title>Kogenate FS Regulatory Post-Marketing Surveillance</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Patients with diagnosis of hemophilia A Treated with KOGENATE FS as their only source of FVIII, decision taken by the investigator to administer KOGENATE FS Signed the informed consent form to participate in this study. For pretreated patients with more than 100 exposure days an inhibitor assessment within three months prior to enrollment should be available For pretreated patients with less than 100 exposure days an inhibitor assessment at baseline should be available For patients with no available inhibitor status, it should be checked as per the recommendation of KFDA Patients are defined as included in the study if there is a documented prescription of KOGENATE FS by the physician. Patients with hypersensitivity to any ingredient of KOGENATE FS or to the protein of mouse or hamster will be excluded.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Kogenate FS</keyword>
	<keyword>Hemophilia A</keyword>
</DOC>